Compare Ascendis Pharma A/S (ASND) vs Devon Energy Corp (DVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Devon Energy Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Devon Energy Corp trades at $42.62 (market cap $48.71B). The key difference: Devon Energy Corp is far larger — about 2.7× Ascendis Pharma A/S's market cap, and Devon Energy Corp pays a 2.46% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DVN | |
|---|---|---|
Market Cap | $17.74B | $48.71B |
Sector | Health | Energy |
52-Week High | $277.18 | $52.07 |
52-Week Low | $163.32 | $31.74 |
Enterprise Value | $18.11B | $55.49B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Devon Energy (DVN) trades at $42.23, up 0.5% with neutral technical signals. The company shows strong fundamentals with a P/E of 11.76 and ROE of 15.13%, though revenue declined from $19.2B in 2022 to $17.2B in 2025. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 beat estimates. Positive sentiment includes 71% analyst buy ratings and a $60.55 consensus target, while activist investor TOMS Capital pushes for asset sales or company sale (Reuters, 2026-06-17).
DVN offers value with discounted valuation and $1B synergy potential from the Coterra merger, but faces oil price volatility and execution risks. The stock trades 30% below analyst targets, presenting upside if operational targets are met, though debt levels and margin compression require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
